NATIONAL VENTURE CAPITAL ASSOCIATION for NATIONAL VENTURE CAPITAL ASSOCIATION

Banking BAN

Implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act(PL 111-203)

Contacted: White House Office; Treasury, Dept of; Securities & Exchange Commission (SEC); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; Office of the Vice President of the United States; Patent & Trademark Office (PTO); Small Business Administration (SBA)

Taxation/Internal Revenue Code TAX

Taxation of carried interest; capital gains tax policy

Contacted: Treasury, Dept of; SENATE; Small Business Administration (SBA); Centers For Medicare and Medicaid Services (CMS); White House Office; Food & Drug Administration (FDA); Patent & Trademark Office (PTO); Office of the Vice President of the United States; HOUSE OF REPRESENTATIVES; Securities & Exchange Commission (SEC)

Copyright/Patent/Trademark CPT

HR3261 Stop Online Piracy Act; S968 Protect IP Act; Oppose SOPA and PIPA - oppose the "Private Right of Action" and the DNS provisions in the bills.

Contacted: Securities & Exchange Commission (SEC); Treasury, Dept of; Office of the Vice President of the United States; Centers For Medicare and Medicaid Services (CMS); Small Business Administration (SBA); White House Office; Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA)

Bills named: H.R. 3261 (112th)

Health Issues HCR

Working with Congress on legislation that would provide reforms to the FDA regulatory process that would promote the advancement of medical innovation for both drugs and medical devices. HR 452/S 668 Health Care Bureaucratic Elimination Act-the Medical Decisions Accountability Act of 2011; lobbying to repeal the independent payment advisory board included in the Patient and Affordable Care Act. Advocating legislation for comprehensive FDA reform for drugs, biologics/medical devices.

Contacted: Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; Small Business Administration (SBA); Treasury, Dept of; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); SENATE; Office of the Vice President of the United States; Securities & Exchange Commission (SEC); White House Office

Bills named: H.R. 452 (112th)

Small Business SMB

S493 SBIR/STTR Reauthorization Act of 2011. Provisions that will allow venture capital companies to compete for SBIR/STTR grants and other SBA programs. HR 1425 Creating Jobs through Small Business Innovation Act.

Contacted: Securities & Exchange Commission (SEC); SENATE; Office of the Vice President of the United States; HOUSE OF REPRESENTATIVES; White House Office; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Small Business Administration (SBA); Treasury, Dept of; Patent & Trademark Office (PTO)

Bills named: H.R. 1425 (112th)

Energy/Nuclear ENG

Renewable energy policy issues: Loan Guarantee Program and Clean Energy Deployment Administration Budget issues for FY 2012. Continuing resolution: Budget issues for FY2012 Energy and Water; ARPA-E funding

Contacted: White House Office; Treasury, Dept of; Patent & Trademark Office (PTO); Securities & Exchange Commission (SEC); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Small Business Administration (SBA); SENATE; Centers For Medicare and Medicaid Services (CMS); Office of the Vice President of the United States

Immigration IMM

Specific lobbying issue: Support for EB6-The Start Up Visa Act allowing foreign born entrepreneurs who receive venture capital and create US jobs to remain in the country.

Contacted: Office of the Vice President of the United States; SENATE; Securities & Exchange Commission (SEC); White House Office; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); Small Business Administration (SBA); Treasury, Dept of

Medical/Disease Research/Clinical Labs MED

Personalized medicine: working with Congress to establish a regulatory approval and reimbursement path for advanced diagnostic products. NVCA submitted comments to FDA and CMS on their FDA/CMA parallel review draft proposal.

Contacted: Small Business Administration (SBA); Office of the Vice President of the United States; Centers For Medicare and Medicaid Services (CMS); Patent & Trademark Office (PTO); Food & Drug Administration (FDA); Securities & Exchange Commission (SEC); White House Office; Treasury, Dept of; SENATE; HOUSE OF REPRESENTATIVES